Medical Research
(H92)
990 on File
CHINESE BIOPHARMACEUTICAL ASSOCIATION-USA INC
Financial strength (30%)
84/100
Reliability (20%)
50/100
Effectiveness (25%)
78/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2025
$130K
Total Revenue
$121K
Total Expenses
$685K
Net Assets
0
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
92.1%
Fundraising Efficiency
N/A
Operating Reserve
67.88x
Liability-to-Asset
0.0%
Revenue Diversification
100.0%
Compared with Peers
FY 2025
Compared with 300 similar organizations
(United States, Medical Research, $100K–$1M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
92.1% | 84.6% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
7.9% | 10.0% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
67.9 mo | 11.7 mo |
P10P90
|
Top quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
100.0% | 92.2% |
P10P90
|
Below median |
|
Surplus margin
Surplus as a share of revenue
|
6.5% | -1.6% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $130K | $121K | $685K | 92.1% | 0 |
| 2023 | $123K | $141K | $682K | 87.6% | 0 |
| 2022 | $68K | $82K | $699K | 87.1% | 0 |
| 2021 | $280K | $31K | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.